



MannKind Corporation to Hold 2010 Third Quarter Financial Results Conference Call on October 29, 2010

October 22, 2010 4:00 AM EDT

MannKind Corporation to Hold 2010 Third Quarter Financial Results Conference Call on October 29, 2010

VALENCIA, Calif., Oct 22, 2010 (BUSINESS WIRE) -- **MannKind Corporation (Nasdaq:MNKD)** will release its 2010 third quarter financial results on Friday, October 29, 2010.

Management of the Company will host a conference call to discuss the third quarter financial results and other Company developments at 9:00 AM EDT on October 29, 2010. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chief Operating Officer, Hakan Edstrom; Corporate Vice President and Chief Financial Officer, Matthew Pfeffer and Corporate Vice President and Chief Scientific Officer, Peter Richardson.

To participate in the live call by telephone, please dial (888) 677-5721 or (210) 839-8507 and use the participant passcode: MANNKIND. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at <http://www.mannkindcorp.com>.

A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (866) 393-0872 or (203) 369-0439. A replay will also be available on MannKind's website for 14 days.

About MannKind Corporation

MannKind Corporation (NASDAQ:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its diabetes pipeline includes AFREZZA[®] and MKC253. MKC253 is currently in phase 1 clinical trials. In March 2009, MannKind submitted a NDA to the FDA requesting approval of AFREZZA for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. In March 2010, MannKind received a Complete Response letter to this NDA from the FDA, requesting additional information. In July 2010, the FDA accepted MannKind's reply to the Complete Response letter and set a PDUFA action date of December 29, 2010. Other products in MannKind's pipeline include the cancer immunotherapy products MKC1106-PP and MKC1106-MT, which are currently in phase 1 clinical trials. MannKind maintains a website at <http://www.mannkindcorp.com> to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

SOURCE: MannKind Corporation

MannKind Corporation

Matthew Pfeffer
Chief Financial Officer
661 775-5300
mpfeffer@mannkindcorp.com